Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Hypertension Drugs Unexpectedly Fight Lysosomal Disorders

February 11, 2008 | A version of this story appeared in Volume 86, Issue 6

In studies on patient-derived cells, two FDA-approved hypertension drugs have proven to be effective at ameliorating multiple characteristics of lysosomal storage diseases, conditions in which macromolecules accumulate in lysosomes (acidic degradation compartments) because of deficient activity by misfolded and degraded enzymes (PLoS Biol., DOI: 10.1371/journal.pbio.0060026). The most common of these disorders is Gaucher disease, which can cause spleen enlargement, anemia, brain damage, and other symptoms. The diseases are currently treated by enzyme-replacement therapy, but enzymes must be injected and the treatments are very expensive. Injected enzymes also can't pass the blood-brain barrier and therefore aren't effective against neurological symptoms. Jeffery W. Kelly and coworkers at Scripps Research Institute now have found that the calcium channel blockers diltiazem (which crosses the blood-brain barrier) and verapamil partially restore the folding and function of defective enzymes in cells derived from patients with lysosomal diseases. The researchers believe the drugs work by upregulating chaperone proteins that help deficient enzymes fold properly.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.